Formulation for alleviating veisalgia symptoms
The embodiments of the present disclosure generally relate to a formulation for alleviating veisalgia symptoms. The formulation can comprise anhydrous caffeine, salicin, and valerian. The components can be delivered within a liquid medium and act synergistically to more effectively relieve veisalgia symptoms than when taken individually.
1. A formulation comprising:
a. anhydrous caffeine;
b. salicin; and
c. valerian; and
wherein the relative weight ratios of anhydrous caffeine:salicin:valerian is 1:1.2-3.8:2.5-8, and
wherein the components act synergistically to alleviate veisalgia symptoms.
2. The formulation of claim 1 , further comprising magnesium chloride.
3. The formulation of claim 1 , further comprising ginger.
4. The formulation of claim 1 , further comprising calcium lactate.
5. The formulation of claim 1 , further comprising trisodium citrate.
6. The formulation of claim 1 , further comprising potassium citrate.
7. The formulation of claim 1 , wherein the relative weight ratios of anhydrous caffeine:salicin:valerian is 1:2-3:4-6.
8. The formulation of claim 1 , wherein the relative weight ratios of anhydrous caffeine:salicin:valerian is 1:about 2.46:about 5.
9. The formulation of claim 1 , further comprising at least one of:
a. stevia;
b. citric acid;
c. sucrose;
d. green coffee bean extract;
e. Calcium Pantothenate-Vitamin B5;
f. Niacinamide;
g. Pyridoxine HCl-Vitamin B6;
h. Biotin-Vitamin B7;
i. Folic Acid;
j. Methylcobalamin-Vitamin B12;
k. Mixed Berry-Natural-COMAX-78.761;
l. Gamma-Aminobutyric Acid (GABA);
m. Sodium Gluconate;
n. Sodium Benzoate; or
o. Potassium Sorbate.
10. A formulation comprising:
a. anhydrous caffeine;
b. salicin;
c. valerian; and
d. ginger;
wherein the relative weight ratios of anhydrous caffeine:salicin:valerian is 1:1.2-3.8:2.5-8, and
wherein the components act synergistically to alleviate veisalgia symptoms.
11. A formulation comprising:
a. anhydrous caffeine;
b. salicin;
c. valerian;
d. magnesium chloride;
e. ginger;
f. calcium lactate;
g. trisodium citrate; and
h. potassium citrate
wherein the relative weight ratios of anhydrous caffeine:salicin:valerian:magnesium chloride:ginger:calcium lactate:trisodium citrate:potassium citrate is about 1:1.2-3.8:2.5-8:0.1-0.4:1:0.3-1.5:10-35:3-10.
12. The formulation of claim 11 , wherein the relative weight ratios of anhydrous caffeine:salicin:valerian:magnesium chloride:ginger:calcium lactate:trisodium citrate:potassium citrate is about 1:2-3:4-6:0.18-0.22:1:0.54-0.88:16-22:4.8-7.2.
13. The formulation of claim 11 , wherein the relative weight ratios of anhydrous caffeine:salicin:valerian:magnesium chloride:ginger:calcium lactate:trisodium citrate:potassium citrate is about 1:2.46:5:0.2:1:0.660:20:6.